| MATERIALS AND METHODS

| Patients and clinicopathological data
The gene expression data of 490 patients with PCa were downloaded from (TCGA, https://tcga-data.nci.nih.gov/tcga/) database by using Firebrowse dataset (http://firebrowse.org/). Level 3 raw expression data of MCM10 from the Illumina HiSeq2000 sequencing platform (Illumina, Inc., San Diego, CA) were downloaded from TCGA data portal. Patient clinical features, including age at diagnosis, days to last follow-up, pathological tumor (T) stage and node (N) stage, were retrospectively obtained from patient records. All the patients were staged using the 2009 tumor-node-metastasis classification of the American Joint Committee on Cancer/International Union Against Cancer. 20 In order to further investigate the prognostic value of MCM10 in PCa, the overall survival rates of patients with high or low MCM10 expression were assessed using the Kaplan-Meier method by using GSE21032 dataset which was reported by Taylor et al. 19 
| Lentiviral constructs and transfections
Recombinant lentiviral vectors carrying MCM10 small interfering RNA (shRNA) were constructed using standard molecular techniques. 293T cells were infected with the recombinant lentiviral vectors using
Lipofectamine 2000 (Thermo Fisher Scientific, Inc., Waltham, MA) to generate stably transfected cells, according to the manufacturer's FIGURE 1 MCM10 expression was upregulated in PCa samples. A-B, TCGA data analysis showed MCM10 expression levels were significantly up-regulated in prostate tumors compared to normal prostate tissues by analyzing all tumor samples (A) and paired samples (B). C, MCM10 expression was higher in more than 90% (35/38) of PCa samples compared with adjacent normal tissues by analyzing the TCGA cohorts. D, MCM10 were highly expressed in PCa cell lines LNCaP, PC-3, DU145. P < 0.05 was considered to indicate a statistically significant difference. *P < 0.05; **P < 0.01; ***P < 0.001. MCM10, Minichromosome maintenance 10 replication initiation factor; PCa, prostate cancer; TCGA, The Cancer Genome Atlas. [Color figure can be viewed at wileyonlinelibrary.com] 
| RT-qPCR
Total RNA was extracted from LNCaP, DU145, and PC-3 cells using 
| Colony formation assays
PC-3-shctrl, PC-3-shMCM10, DU145-shctrl, and DU145-shMCM10 cells were plated on 60-mm plates (0.5 × 103 cells per plate) and cultured at 37°C for 10 days. The colonies were stained with 1% crystal violet (Sigma-Aldrich; Merck KGaA) for 30 s following fixation with 10% formaldehyde for 5 min at room temperature.
| Microarray and expression datasets
Total RNA was extracted from three shMCM10 samples and three shRNA control samples using TRIzol reagent (Invitrogen; Thermo Fisher Scientific) and the RNeasy mini kit (Qiagen GmbH, Hilden, Germany).
Total RNA was quantified by the NanoDrop ND-2000 (Thermo Fisher Scientific, Inc.) and the RNA integrity was assessed using Agilent
Bioanalyzer 2100 (Agilent Technologies, Inc., Santa Clara, CA).
Global expressions of mRNAs in three MCM10 shCtrl samples and three shMCM10 were examined using the Gene Chip Prime View The cell apoptosis analysis results are presented as the mean ± standard deviation (n = 3). P < 0.05 was considered to indicated a statistically significant difference. *P < 0.05; **P < 0.01; ***P < 0.001. MCM10, Minichromosome maintenance 10 replication initiation factor; Ctrl, control; sh, short hairpin. [Color figure can be viewed at wileyonlinelibrary.com]
Human Gene Expression Array (Thermo Fisher Scientific, Inc.). The sample labeling, microarray hybridization and washing were performed according to the manufacturer's protocols. Raw data were normalized using the log2 scale. Two-class unpaired significance analysis of microarray (19) was employed to filter significantly differentially expressed mRNAs between shCtrl and shMCM10. To begin with, the raw data were normalized using the quantile algorithm. The probes for which ≥1 out of two conditions have flags in "P" were selected for further data analysis. Differentially expressed mRNAs were subsequently identified through fold change. The threshold set for upregulated and downregulated genes was a fold change ≥1.5.
Subsequently, Kyoto Encyclopedia of Genes and Genomes (KEGG)
pathway and Gene Ontology (GO) analyses of differently expressed downstream genes of MCM10 were performed using an Ingenuity
Pathway Analysis system (https://www.qiagenbioinformatics.com/ products/ingenuity-pathway-analysis/www.ingenuity.com).
| Statistical analysis
The differences between two groups in gene expression, cell apoptosis, colony number and migrated cell number were evaluated using Student's t-test. The statistical significance of differences in multiple groups was determined by using the Kruskal-Wallis H test.
Kaplan-Meier analysis, followed by the log-rank test, were utilized to assess the association between MCM10 and overall survival and biochemical recurrence (BCR)-free survival of PCa. All statistical analyses were conducted using GraphPad Prism software 5.0 (GraphPad Software, Inc., La Jolla, CA). P < 0.05 was considered to indicate a statistically significant difference.
3 | RESULTS
| MCM10 was upregulated in PCa
In order to evaluate the expression pattern of MCM family members in between PCa samples and normal samples (Supplementary Figure S1 ).
Among these differently expressed MCM family members, we focused on MCM10 in this study, which was not previously reported in PCa.
We found MCM10 was significantly upregulated in PCa samples compared to normal tissues. Of note, more than 90% of PCa tissues expressed high levels of MCM10, while only ∼10% (3/38) of matched normal tissues expressed high levels of MCM10 ( Figure 1C ).
Additionally, we also observed MCM10 was highly expressed in PCa cell lines by using RT-PCR analysis ( Figure 1D ). Furthermore, we evaluated the correlation of MCM10 with DNA methylation and MCM10 amplification or deletion. From our results, we observed MCM10 expression was not significantly correlated with the CNV status (Supplementary Figure S3A) or DNA methylation status in PCa (Supplementary Figure S3B) . Androgen receptor (AR) is the most important regulator of PCa progression. We found MCM10 was not a AR-regulated gene by analyzing GSE18684 dataset.
To characterize the functions of MCM10 in PCa, MCM10
shRNA was used to knockdown MCM10 expression at the mRNA and protein levels. Compared to treatment with the scrambled shRNA control, MCM10-specific shRNA substantially decreased MCM10 mRNA and protein levels in DU145, PC-3, and LNCaP cells (Figure 2A-F) . 
| MCM10 knockdown inhibits cell proliferation in PCa cells
Furthermore, we evaluated the effects of MCM10 on cell proliferation in DU145 and PC-3 cells. Celigo Cell Counting indicated that DU145
( Figures 3A and 3C ) and PC-3 ( Figures 3B and 3D ) cell growth were slower in MCM10-shRNA-transfected group than in negative control group (P < 0.05) after 4 days. In addition, we performed MTT assay to evaluate the growth rate of DU145 and PC-3 after MCM10
knockdown. As shown in Figure 3 , we observed MCM10 knockdown could inhibit cell proliferation in DU145 ( Figure 3E ) and PC-3 ( Figure 3F ) cells. 5A and 5B) and PC-3 ( Figures 5C and 5D ) cells to form colonies (P < 0.05).
| Suppression of MCM10 expression induces apoptosis of PCa cells
| Identification of MCM10 regulated genes in PCa
In this study, mRNA expression profiling was used to identify MCM10 and PTEN signaling ( Figure 6E ).
| Knockdown of MCM10 regulates cell proliferation related genes in PCa
In order to explore mechanism of MCM10 regulating cell proliferation, we constructed a network ( Figure 7) . Furthermore, 30 downstream targets (14 down-regulated and 16 up-regulated genes after MCM10
FIGURE 8
Knockdown of MCM10 regulates cell proliferation-related genes in PC-3. A, Heatmap showed expression levels of 30 MCM10 targets after MCM10 knockdown in PC-3. B, Real-time reverse transcription PCR analysis showed 13 genes were downregulated after MCM10 knockdown. C, Real-time reverse transcription PCR analysis showed 15 genes were up-regulated after MCM10 knockdown in PC-3. The results are presented as the mean ± standard deviation (n = 3). *P < 0.05; **P < 0.01; ***P < 0.001. Ctrl, control; MCM10, minichromosome maintenance 10 replication initiation factor; PCa, prostate cancer; sh, short hairpin. [Color figure can be viewed at wileyonlinelibrary.com] CUI ET AL.
| 1307 knockdown) of MCM10 were selected for further validation ( Figure 8A ).
Consistent with our microarray analysis, we found 13 genes (MCM10,   WWTR1, CYR61, SLC39A10, NCOA3, MAD2L1, EGFR, CAV1, SATB2, SPP1, PIK3CB, MDM2, and MAPK9) were suppressed after MCM10 knockdown ( Figure 8B ). However, 15 genes (KLF4, NR3C1, JUN, ING3,   CDKN1A, TP53I3, PTK2B, CDK6, OLR1, INHBA, TGFBR3, SNAI2, CD47, ICAM1, and LTB) were induced following MCM10 knockdown ( Figure 8C ). These results together with our previous analysis showed that MCM10 acts as a key regulator in PCa progression.
| Upregulation of MCM10 predicts a poor prognosis in PCa
In the present study, we also evaluated the association between MCM10 mRNA expression levels in tumor tissues and clinicopathological factors in PCa. We found that MCM10 levels were higher in N1
stage PCa samples than in N0 stage PCa samples ( Figure 9A ).
Moreover, analysis of the TCGA database demonstrated that a significantly higher expression of MCM10 was observed in Gleason 7 (P < 0.05), Gleason 8 (P < 0.01), and Gleason 9 (P < 0.001) patients compared with Gleason 6 patients ( Figure 9B ).
Kaplan-Meier curve method was performed to assess the association of MCM10 expression with BCR-free survival and overall survival in PCa patients by using Taylor and TCGA dataset. As demonstrated in Figure 9C , compared with patients with high MCM10 expression, the BCR-free survival rates were significantly higher in patients with low MCM10 expression in the TCGA dataset (P < 0.01).
By analyzing Taylor dataset, the overall survival rates were also observed to be higher in MCM10-low compared to MCM10-high patients ( Figure 9D , P < 0.01, MCM10-first quartile vs fourth quartile).
| DISCUSSION
PCa is one of the most frequently diagnosed types of cancer worldwide. 2 Although PSA is the most widely used biomarker of PCa, the poor sensitivity and specificity of PSA level testing are still a big
FIGURE 9
Upregulation of MCM10 predicts a poor prognosis in PCa. A, MCM10 expression was upregulated in N1 PCa cases compared with N0 PCa cases. B, MCM10 expression was upregulated in Gleason 7, Gleason 8, and Gleason 9 PCa cases compared with Gleason 6 cases. C, The BCR-free survival rates were higher in patients with low MCM10 expression in the TCGA dataset. D, By analyzing Taylor dataset, the overall survival rates were also observed to be higher in MCM10-low compared to MCM10-high patients. *P < 0.05; **P < 0.01; ***P < 0.001. MCM10, Minichromosome maintenance 10 replication initiation factor; PCa, prostate cancer; TCGA, The Cancer Genome Atlas; TPM, transcripts per kilobase million. [Color figure can be viewed at wileyonlinelibrary.com] challenge when applying it for PCa diagnosis. [22] [23] [24] In the present study, we knocked down MCM10 expression in PCa cells and evaluated the effect of its knockdown on cell proliferation, colony formation, and cell apoptosis. We observed MCM10 knockdown significantly inhibited cell proliferation and colony formation, but promoted cell apoptosis in PCa. As far as we know, there are no reports regarding the role of MCM10 in PCa, and this is the first study to report MCM10 acts as an oncogene in PCa.
In previous studies, several upstream regulators of MCM10 had been revealed. For example, The E2F/Rb pathway 29 and GATA6 30 could regulate MCM10 transcription. E3 ubiquitin ligase RBBP6 promoted MCM10 transcription by ubiquitinating and destabilizing the transcriptional repressor ZBTB38. 10 MiRNAs, such as miR-215, were also reported as MCM10 regulators by inhibiting its expression. 31 However, the downstream genes of MCM10 in PCa remained unknown. In order to further investigate the functional roles of MCM10 in PCa, bioinformatics analysis was performed, in combination with a high-throughput array. A total of 1015 genes were identified to be upregulated and 808 genes were identified to be downregulated following MCM10 knockdown. Our analysis showed MCM10 was associated with cancer, cell death, apoptosis, cell death of tumor cell lines, necrosis, and cell cycle progression. KEGG analysis showed MCM10 was associated with Glucocorticoid Receptor signaling, IGF-1 signaling, and p53 signaling.
To reveal how MCM10 effect cell proliferation, we constructed a proliferation-related network. RT-PCR analysis results showed 13 genes (MCM10, WWTR1, CYR61, SLC39A10, NCOA3, MAD2L1, EGFR, CAV1,   SATB2, SPP1, PIK3CB, MDM2, and MAPK9) were suppressed and 15   genes (KLF4, NR3C1, JUN, ING3, CDKN1A, TP53I3, PTK2B, CDK6,   OLR1, INHBA, TGFBR3, SNAI2 , CD47, ICAM1, and LTB) were induced after MCM10 knockdown in PCa. Of note, previous studies had reported these genes were associated with cancer cell proliferation. For instance, CYR61 promoted breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis 32, 33 and PIK3CB was required for the growth of ERBB2 and RAS driven tumors. 
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